Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.
Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B. Bond TC, et al. Among authors: schwartzberg l. J Oncol Pharm Pract. 2018 Sep;24(6):412-423. doi: 10.1177/1078155217714859. Epub 2017 Jun 14. J Oncol Pharm Pract. 2018. PMID: 28614980 Free PMC article. Review.
Neutropenia: etiology and pathogenesis.
Schwartzberg LS. Schwartzberg LS. Clin Cornerstone. 2006;8 Suppl 5:S5-11. doi: 10.1016/s1098-3597(06)80053-0. Clin Cornerstone. 2006. PMID: 17379162 Review.
Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
Schwartzberg LS, Bhat G, Peguero J, Agajanian R, Bharadwaj JS, Restrepo A, Hlalah O, Mehmi I, Chawla S, Hasal SJ, Yang Z, Cobb PW. Schwartzberg LS, et al. Oncologist. 2020 Aug;25(8):e1233-e1241. doi: 10.1634/theoncologist.2020-0105. Epub 2020 Jun 16. Oncologist. 2020. PMID: 32476162 Free PMC article. Clinical Trial.
First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.
Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS. Vogel CL, et al. Among authors: schwartzberg ls. J Clin Oncol. 2005 Feb 20;23(6):1178-84. doi: 10.1200/JCO.2005.09.102. J Clin Oncol. 2005. PMID: 15718314 Clinical Trial.
317 results